Почетна › Колоректален карцином › Северна Каролина › Durham
Клинички испитувања за Колоректален карцином во Durham, NC
29 студии за Колоректален карцином бараат учесници на локации во и околу Durham (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Се регрутираФаза 3
- Duke University Medical Center /ID# 279322, Durham
The Vanguard Study: Testing a New Way to Screen for Cancer
Се регрутираДобредојдени се здрави волонтери
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Се регрутираФаза 2
- University of North Carolina, Chapel Hill · на 10 милји
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
- Durham VA Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- Duke University, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Се регрутираФаза 1
- Exelixis Clinical Site #12, Durham
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Се регрутираФаза 2
- University of North Carolina Medical Center /ID# 267786, Chapel Hill · на 10 милји
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Се регрутираФаза 1/2
- Duke Cancer Center, Durham
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Се регрутираФаза 3
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Се регрутираФаза 3
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Се регрутираФаза 3
- Duke University Medical Center, Durham
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Се регрутираФаза 1/2
- Duke University Medical Center, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Се регрутираФаза 1
- Duke University Medical Center, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Се регрутираФаза 1/2
- Duke University School of Medicine, Durham
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Се регрутираФаза 3
- The University of North Carolina At Chapel Hill, Chapel Hill · на 10 милји
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Се регрутираФаза 3
- Duke Cancer Center, Durham
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- Duke University Medical Center, Durham
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Се регрутираФаза 2
- Duke University Medical Center - Duke Cancer Center, Durham
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Се регрутираФаза 1/2
- Duke University, Durham
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Се регрутираФаза 1/2
- GSK Investigational Site, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- Duke Cancer Center, Durham
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Се регрутираФаза 3
- Duke University Hospital, Durham
- Duke University Medical Center, Duke Cancer Center, Durham
- Duke University Medical Center, Durham
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Се регрутираФаза 2
- Duke University Medical Center, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Се регрутира
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · на 10 милји
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Се регрутираФаза 2
- Duke University Medical Center /ID# 279457, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Се регрутираФаза 1
- Research Site, Durham
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Се регрутираФаза 1/2
- Duke University Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- Duke Cancer Center, Durham
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Се регрутира
- Duke Cancer Institute, Durham
Испитувања за Колоректален карцином во други градови
- Houston, TX102 студии
- New York City, NY78 студии
- Nashville, TN69 студии
- Boston, MA64 студии
- Los Angeles, CA60 студии
- Arlington, VA52 студии
- St. Louis, MO51 студија
- San Antonio, TX46 студии
- Philadelphia, PA44 студии
- Grand Rapids, MI40 студии
- Baldwin Park, CA37 студии
- Chicago, IL35 студии
Други студии во Durham
- Рак на дојка64 студии
- Рак (сите типови)58 студии
- Рак на бели дробови со не-мали клетки39 студии
- Множен миелом37 студии
- Метастатски карцином33 студии
- Акутна миелоидна леукемија33 студии
- Рак на простата32 студии
- Рак на бели дробови32 студии
- Хронична лимфоцитна леукемија27 студии
- Карцином на јајниците27 студии
- Срцева слабост26 студии
- Карцином на панкреасот24 студии
Од ClinicalTrials.gov, податоци преземени 7.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.